Oxford BioMedica plc (OXB.L)

Could it be that Novartis is negotiating to buy Oxford BioMedica outright?

Good luck and GOD bless,

George

Oxford BioMedica announces further capacity expansion with new facility
Lentiviral vector bioprocessing market expected to grow to $800m by 2026

Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector bioprocessing market (excluding milestones and royalties)

Since OXB (OXB.L) is trading at about 979.67 pence per share in London, then OXBDF should be trading at about $13.10 USD per share in the USA.

Good luck and GOD bless,

George

"....AXO-Lenti-PD gene therapy has been developed by reengineering ProSavin to improve dopamine plus levodopa production by ten times...."

https://marketrealist.com/2018/06/why-axovant-sciences-stock-rose-in-week-ended-june-8

Good luck and GOD bless,

George

Oxbdf.... In April the Group has joined a Consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine candidate for COVID-19 called ChAdOx1 nCoV-19. AstraZeneca subsequently entered into an agreement with Oxford University for the global development and distribution of the vaccine on 30th April.  While the potential impact on the Group is currently uncertain, should clinical trials be successful the Group will provide access to its large scale GMP manufacturing facilities including Oxbox to support the manufacturing scale up for Oxford University and AstraZeneca.

On to the second deal with Axovant around our Parkinsons' drug OXB-102, now known as AXO-Lenti-PD. It's a worldwide licensing agreement here. Headline value of the deal was $842.5 million. The $30 million upfront here, $55 million was specified development milestones, and a further $757.5 million was specified regulatory and sales milestones. So on the drug here, the royalties we get are higher than we'd normally get in a partnership deal. We get tiered 7% to 10% on sales.

In March 2019, Axovant reported their data from the first cohort of the Phase 1/2 trial and are now planning to move into the second cohort of treatment in the second quarter. Very exciting in this, we're so excited where it can go.

Products in Parkinson's in 2016 sold $3.1 billion, set to rise on our forecast to about $8.8 billion by 2026. It's a huge market we are involved.

https://seekingalpha.com/article/4248943-oxford-biomedicas-oxbdf-ceo-john-dawson-q4-2018-results-earnings-call-transcript?part=single

Good luck and GOD bless,

Oxford Biomedica To Get Milestone Payment As Axovant Doses Patient LONDON (Alliance News) - Oxford Biomedica on Tuesday said that Axovant Gene Therapies Ltd has ...
Alliance News30 April, 2019 | 5:24PMEmail Form
LONDON (Alliance News) - Oxford Biomedica on Tuesday said that Axovant Gene Therapies Ltd has triggered a USD15 million milestone payment to the company.

Axovant has announced the dosing of the first patient of the second cohort in the Sunrise-PD phase two trial of AXO-Lenti-PD in Parkinson's disease patients, Oxford Biomedica said, which has triggered the payment to the London-listed firm under an agreement signed in June.

Up to six patients will be dosed in this second cohort, Oxford Biomedica said. To date, the patient has experienced no complications related to the surgery or to administration of the vector and has been discharged home as planned.

Oxford Biomedica shares closed down 0.1% at 697.073 pence on Tuesday.

http://www.morningstar.co.uk/uk/news/AN_1556641470134623300/oxford-biomedica-to-get-milestone-payment-as-axovant-doses-patient.aspx

Good luck and GOD bless,

Quote:
First two patients dosed in SUNRISE-PD phase 2 trial of AXO-Lenti-PD for Parkinson's disease and initial patient dosed with AXO-AAV-GM2; data from both programs expected in March 2019

Axovant Sciences Ltd. intends to change its name to Axovant Gene Therapies Ltd. and ticker symbol to “AXGT” to reflect its exclusive focus on gene therapies

http://investors.axovant.com/news-releases/news-release-details/axovant-announces-third-fiscal-quarter-2018-financial-results

Good luck and GOD bless,

Oxford scientist says its vaccine is making headway, could show efficacy by June

https://www.nbcnews.com/politics/meet-the-press/oxford-scientist-says-its-vaccine-making-headway-could-show-efficacy-n1198946

Good luck and GOD bless,

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

http://investors.axovant.com/news-releases/news-release-details/axovant-announces-dosing-first-patient-clinical-study-axo-lenti

Good luck and GOD bless,

A MUST READ REGARDING TODAY'S NEWS!!!

Quote:
UPDATED: Early data snapshots of Axovant’s gene therapies for Parkinson’s

Following the collapse of its neuro-focused strategy, Axovant’s foray into gene therapies — with their potential for one-shot, long-term cures — has generated considerable interest. On Monday, the biotech provided an early positive snapshot of two of its programs: in Parkinson’s and infantile Tay-Sachs disease.

Two patients were given the lowest dose of Axovant’s Parkinson’s gene therapy — AXO-Lenti-PD — as part of a mid-stage study called SUNRISE-PD. Patients were assessed three months after their dose, having been washed out of their oral levodopa therapy — the gold standard treatment for Parkinson’s. On a physician-rated scale (UPDRS) assessing motor function (the Part III score), both patients experienced an improvement. The scale measures scores ranging from 0 to 108, with lower scores indicating improvement. At three months, one patient saw an improvement of 14 points, the other 36 points — translating to an average improvement of 25 points or a mean 42% from baseline, Axovant said.

Progress was also observed on other parts of the UPDRS scale. In activities of daily living (UPDRS Part II), patients experienced an average improvement of 22 points from baseline, while for complications of therapy (UPDRS Part IV), they saw a mean improvement of 7 points from baseline.

Axovant licensed the investigational gene therapy, as well as the predecessor product ProSavin, from Oxford BioMedica last year for $30 million upfront. AXO-Lenti-PD is designed to deliver three genes — tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino acid decarboxylase — via a lentiviral vector to encode a set of critical enzymes required for dopamine synthesis to restore steady levels of dopamine in the brain in one shot.

These results suggest that the lowest dose of AXO-Lenti-PD at three months may have greater efficacy compared to the highest dose of ProSavin previously tested, Axovant said.

“The mechanism of action of AXO-Lenti-PD…as well as our prior clinical experience with ProSavin, led us to expect that the major benefit would be in improving the OFF state – and the results so far are very encouraging in this regard,” said Roger Barker, one of the principal investigators on the SUNRISE-PD study.

Based on feedback from the data monitoring committee, Axovant is going to test a second dose of the therapy, and the first administration of that new dose is expected in the second quarter, the company said.

https://endpts.com/early-data-snapshots-of-axovants-gene-therapies-for-parkinsons-tay-sachs-appear-promising/

Now follow this Shiela Roy as in the previous ProSavin trial. Her improvement was in step jumps over several years at least and she wrote a book or books after treatment.

“There is hope for turning this condition around”
PERSPECTIVES Author: Sheila RoyPublished: 9 April 2015 Sheila Roy (centre)
At a time when trial subjects are in short supply, people like Sheila Roy (pictured above, centre) ensure the Parkinson’s community benefits from the experimental research. One of the first people in the world to test ProSavin, she has written the following account four years into her trial – recounting the highs, the lows and ultimately the “life-changing” improvement to her quality of life

I was diagnosed with Parkinson’s in 1995 and have lived with this life affecting condition for 20 years, one third of my life. This disease has challenged my ability to function in every possible way. I lost confidence, dignity and hope. For the first 18 years I experienced mobility problems, falls, constant pain, sleep deprivation, screaming nightmares, dyskinesia, ‘freezing’, and in my case, spontaneous closure of my vocal cords and being unable to breath.

I was spiralling downwards with little hope. My day was so unpredictable. The transition from extreme involuntary movements to completely frozen took four seconds, which meant that I was unable to get into a safe position. Often the freezing would last for up to two and half hours, and took some time to return to moving around again.

At this time I spent about 60% of each day ‘off’ which meant that I spent long periods sitting and waiting until I came back ‘on’ again. Only 20% of my day was ‘on’ but this was blighted by involuntary movement making it hard to do anything. It led to a withdrawal from society and I was exhausted by the constant movement. My sleeping was erratic and I would frequently wake my husband up with screaming nightmares.

All of these symptoms changed me into a person that I no longer recognised. In 2010, when I was thinking that things could not get any worse, they did just that. One night the house caught fire and my husband bec

In a cell and gene therapy sweet spot Oxford BioMedica 4 June 2019 Outlook

https://www.edisongroup.com/publication/in-a-cell-and-gene-therapy-sweet-spot/24313

Good luck and GOD bless,

Quote:
Dosed second patient in the SUNRISE-PD phase 2 clinical trial of AXO-Lenti-PD in November 2018, with data expected in March 2019

https://globenewswire.com/news-release/2018/12/06/1662935/0/en/Axovant-Announces-Feedback-From-FDA-Meeting-Regarding-AXO-Lenti-PD-for-Parkinson-s-Disease-and-Progress-in-Ongoing-SUNRISE-PD-Phase-2-Clinical-Trial.html

Good luck and GOD bless,

Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning

Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using the cloud and machine learning.

Cell and gene therapy has the potential to transform medicine, providing long-term and potentially curative treatment options for a wide range of diseases. The first products are already approved and available for patients however, with the increase in demand for these innovative therapies comes manufacturing challenges for the delivery systems that enable them.

The collaboration will combine the expertise of Oxford Biomedica researchers in cutting edge vector development and large scale manufacture and the team within the Station B initiative at Microsoft to explore new ways to increase the yield and improve the purity of Oxford Biomedica’s lentiviral vectors, while further reducing the cost. Oxford Biomedica will contribute large data sets for analysis via the Microsoft Azure intelligent cloud platform. Microsoft, in collaboration with Oxford Biomedica scientists, will utilise its cloud computing and machine learning capabilities to develop in silico models and novel algorithms to help advance the next generation of cell and gene delivery technology. The collaboration will run for an initial two-year period and may be extended by either party.

Jason Slingsby, Chief Business Officer of Oxford Biomedica, said: “Our LentiVector® gene delivery platform is recognised as a leading solution by major industry players but developing next-generation manufacturing technologies is complex and often involves uncertain outcomes.

“The collaboration with Microsoft Research will harness our rich data resources to offer greater insights into the biological processes required to enhance quality and optimise yields of lentiviral vectors. It builds on our digital framework initiative, established in 2018, and the work underway in our collaboration with Synthace to rapidly and flexibly design, simulate and execute complex experimental designs to develop next generation manufacturing processes, including with stable producer cell lines for lentiviral vectors. Our goal is to enable faster, cheaper and more reliable manufacture of high quality next-generation cell and gene therapies to allow more patients to benefit.”

Andrew Phillips, Head of Biological Computation at Microsoft, said: “Programming biology has the potential to solve some of the world’s toughest problems in medicine, and to lay the foundations for a future bioeconomy based on sustainable technology. Oxford Biomedica is at the cutting edge of cell and gene therapy delivery and their highly sophisticated manufacturing processes generate a vast wealth of valuable data. We anticipate that by combining computational modelling, lab automation, machine learning and the power of the cloud, we can help them in their quest to make existing treatments more cost effective and in future to develop groundbreaking new treatments.

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-announces-rd-collaboration-microsoft-improve-gene-and-cell

Good luck and GOD bless,

Sheila Roy is a true pioneer for ProSavin gene therapy for Parkinson's disease.

AXO-Lenti-PD could be 5 to 10 times more potent than ProSavin.

https://www.dailymotion.com/video/xq66qh

Good luck and GOD bless,